Ohtomo Kazuyoshi, Arita Reiko, Shirakawa Rika, Usui Tomohiko, Yamashita Hiroharu, Seto Yasuyuki, Yamagami Satoru
Department of Ophthalmology, Japan Community Healthcare Organization, Tokyo Shinjuku Medical Center, Tokyo, Japan.
Department of Ophthalmology, University of Tokyo Hospital, Tokyo, Japan.
Transl Vis Sci Technol. 2018 Dec 28;7(6):37. doi: 10.1167/tvst.7.6.37. eCollection 2018 Nov.
The aim of this prospective, noncomparative, observational case series was to evaluate changes to meibomian gland morphology in patients undergoing S-1 chemotherapy with the use of noninvasive meibography and analytical software.
Patients aged ≥20 years and undergoing S-1 chemotherapy were included. Ophthalmologic examinations were performed before S-1 administration (Pre) and at 1, 3, and 6 months afterward (1M, 3M, and 6M, respectively). Meibography images were analyzed using analytical software. The ratio of the total meibomian gland area relative to the whole measurement area (meibomian gland area ratio [MGAR]) and the rate of change to the MGAR (MGAR at Pre, 1M, 3M, or 6M)/(MGAR at Pre) × 100 were calculated.
In total, 28 eyelids of seven men (mean age, 68.9 ± 6.3 years) were studied. The mean MGAR of the upper and lower eyelids significantly decreased at 3M ( = 0.0246 and = 0.00892, respectively) and 6M ( < 0.0001 and < 0.0001, respectively). There was a significant negative correlation between the cumulative dose of S-1 and the rate of change to the MGAR of the upper ( < 0.0001, = -0.77) and lower ( < 0.0001, = -0.785) eyelids. However, there was no other significant difference.
The meibomian gland area decreased after S-1 administration with significant correlations between the rate of change to the MGAR and the mean cumulative dose of S-1.
Systemic S-1 administration decreased the MGAR in a dose-dependent manner; thus, clinicians should pay more attention to morphologic changes to the meibomian glands during early treatment with S-1.
本前瞻性、非对照、观察性病例系列研究旨在使用无创睑板腺造影术和分析软件评估接受S-1化疗患者睑板腺形态的变化。
纳入年龄≥20岁且正在接受S-1化疗的患者。在给予S-1之前（Pre）以及之后1、3和6个月（分别为1M、3M和6M）进行眼科检查。使用分析软件分析睑板腺造影图像。计算睑板腺总面积相对于整个测量区域的比率（睑板腺面积比率[MGAR]）以及MGAR的变化率（Pre、1M、3M或6M时的MGAR）/（Pre时的MGAR）×100。
共研究了7名男性（平均年龄68.9±6.3岁）的28只眼睑。上下眼睑的平均MGAR在3M时（分别为 = 0.0246和 = 0.00892）和6M时（均<0.0001）显著降低。S-1的累积剂量与上睑（<0.0001， = -0.77）和下睑（<0.0001， = -0.785）MGAR的变化率之间存在显著负相关。然而，没有其他显著差异。
给予S-1后睑板腺面积减小，MGAR变化率与S-1平均累积剂量之间存在显著相关性。
全身给予S-1以剂量依赖性方式降低MGAR；因此，临床医生在S-1早期治疗期间应更多关注睑板腺的形态变化。
